By simultaneously inhibiting ER and Hsp90, a multitarget drug can not only tackle the primary tumor growth mechanism mediated by ER but also interfere with cellular stress mechanisms and the stabilization of oncoproteins mediated by Hsp90. The gene discussed is HSP90AA1; the disease is neoplasm.